Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;28(5):1063-1071.
doi: 10.1038/s41591-022-01753-y. Epub 2022 Feb 21.

Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants

Hung Fu Tseng  1   2 , Bradley K Ackerson  3 , Yi Luo  3 , Lina S Sy  3 , Carla A Talarico  4 , Yun Tian  3 , Katia J Bruxvoort  5 , Julia E Tubert  3 , Ana Florea  3 , Jennifer H Ku  3 , Gina S Lee  3 , Soon Kyu Choi  3 , Harpreet S Takhar  3 , Michael Aragones  3 , Lei Qian  3
Affiliations

Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants

Hung Fu Tseng et al. Nat Med. 2022 May.

Erratum in

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron (B.1.1.529) variant is highly transmissible with potential immune escape. We conducted a test-negative case-control study to evaluate mRNA-1273 vaccine effectiveness (VE) against infection and hospitalization with Omicron or Delta. The large, diverse study population included 26,683 SARS-CoV-2 test-positive cases with variants determined by S gene target failure status (16% Delta and 84% Omicron). The two-dose VE against Omicron infection at 14-90 days was 44.0% (95% confidence interval, 35.1-51.6%) but declined quickly. The three-dose VE was 93.7% (92.2-94.9%) and 86.0% (78.1-91.1%) against Delta infection and 71.6% (69.7-73.4%) and 47.4% (40.5-53.5%) against Omicron infection at 14-60 days and >60 days, respectively. The three-dose VE was 29.4% (0.3-50.0%) against Omicron infection in immunocompromised individuals. The three-dose VE against hospitalization with Delta or Omicron was >99% across the entire study population. Our findings demonstrate high, durable three-dose VE against Delta infection but lower effectiveness against Omicron infection, particularly among immunocompromised people. However, three-dose VE of mRNA-1273 was high against hospitalization with Delta and Omicron variants.

PubMed Disclaimer

Conflict of interest statement

All authors have completed the International Committee of Medical Journal Editors uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare the following: H.F.T., B.K.A., Y.L., L.S.S., Y.T., J.E.T., A.F., J.H.K., G.S.L., S.K.C., H.S.T., M.A. and L.Q. are employees of Kaiser Permanente Southern California, which has been contracted by Moderna, Inc. to conduct this study. K.J.B. is an adjunct investigator at Kaiser Permanente Southern California. C.A.T. is an employee of and a shareholder in Moderna, Inc. H.F.T. received funding from GlaxoSmithKline and Seqirus unrelated to this manuscript. H.F.T. also served on advisory boards for Janssen and Pfizer. B.K.A. received funding from GlaxoSmithKline, Dynavax, Seqirus, Pfizer and Genentech for work unrelated to this study and has served on advisory boards for GlaxoSmithKline. Y.L. received funding from GlaxoSmithKline, Seqirus and Pfizer unrelated to this manuscript. L.S.S. received funding from GlaxoSmithKline, Dynavax and Seqirus unrelated to this manuscript. Y.T. received funding from GlaxoSmithKline unrelated to this manuscript. K.J.B. received funding from GlaxoSmithKline, Dynavax, Pfizer, Gilead and Seqirus unrelated to this manuscript. J.E.T. received funding from Pfizer unrelated to this manuscript. A.F. received funding from Pfizer, GlaxoSmithKline and Gilead unrelated to this manuscript. J.H.K. received funding from GlaxoSmithKline unrelated to this manuscript. G.S.L. received funding from GlaxoSmithKline unrelated to this manuscript. S.K.C. received funding from Pfizer and the Pancreatic Cancer Action Network unrelated to this manuscript. H.S.T. received funding from GlaxoSmithKline, Pfizer, ALK and Wellcome unrelated to this manuscript. M.A. received funding from Pfizer unrelated to this manuscript. L.Q. received funding from GlaxoSmithKline and Dynavax unrelated to this manuscript.

Figures

Fig. 1
Fig. 1. Flowchart of selection of cases and controls.
Steps for selection of 26,683 cases and 109,662 controls by inclusion and exclusion criteria and subsequent matching in one-dose, two-dose and three-dose analyses.
Fig. 2
Fig. 2. VE of two doses of mRNA-1273 against Omicron and Delta variants by time since vaccination (n = 70,536 individuals).
Waning effectiveness of two doses of mRNA-1273 vaccine against Omicron infection (red line) and Delta infection (blue line) within 365 days after receipt of second dose. Data are presented as VE ± 95% CI.
Fig. 3
Fig. 3. VE of three doses of mRNA-1273 against Omicron and Delta variants by time since vaccination among immunocompetent population (n = 42,714 individuals).
Effectiveness of three doses of mRNA-1273 vaccine against Delta infection (blue line) and Omicron infection (red line), comparing effectiveness by time since third dose (14–60 days or >60 days). Data are presented as VE ± 95% CI.
See this image and copyright information in PMC

References

    1. Wolter, N. et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa. Lancet399, 437–446 (2022). - PMC - PubMed
    1. Garcia-Beltran, W. F. et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell185, 457–466 (2022). - PMC - PubMed
    1. Doria-Rose, N. A. et al. Booster of mRNA-1273 strengthens SARS-CoV-2 Omicron neutralization. Preprint at https://www.medrxiv.org/content/10.1101/2021.12.15.21267805v1 (2021). - DOI
    1. Cele, S. et al. SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. Preprint at https://www.medrxiv.org/content/10.1101/2021.12.08.21267417v1 (2021). - DOI
    1. Wilhelm, A. et al. Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies. Preprint at https://www.medrxiv.org/content/10.1101/2021.12.07.21267432v2 (2021). - DOI

Publication types

Substances

Supplementary concepts